.RESEARCH STUDY EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to conventional procedure for muscle-invasive bladder cancer strengthened event-free and overall survival, denoting a new therapy choice for this condition.